News

Explore how glaucoma care merges with refractive cataract surgery, covering MIGS choices, ocular surface optimization, and IOL selection to maximize vision quality.

Most eyes were fluid-free after 24 weeks with visual acuity increases observed in some.

Rahul Tonk, MD, MBA, gives an overview of the cases he discussed during his portion of a segment on refractive surgery.

Risk stratification, patch graft selection, tube repositioning, and multidisciplinary care all play a role in minimizing erosion and protecting long-term outcomes.

Nicole Bajic, MD, outlines key takeaways from her case study involving Descemet membrane detachment occurring in the setting of focal canaloplasty using the Streamline Surgical System.

Pathik P. Amin, OD, FAAO, details his segment of an educational track session on glaucoma at this year's conference.

The 22nd International Scientific Symposium on Ophthalmic Imaging will take place September 18 to 19, 2026 in Singapore, featuring sessions on multimodal imaging, OCT, AI, and next-generation imaging technologies.

Across sessions, speakers emphasized that AI is not a replacement for physician judgment.

Shameema Sikder, MD, details a session she presented with Roomasa Channa, MD, at EnVision Summit 2026.

Real-world data shows systemic immunomodulators beat local steroids for chronic uveitis, cutting glaucoma, cataract, CME, and ERM risks.

Bonnie An Henderson, MD, founder of EnVision Summit, highlights how the annual conference integrates MD and OD tracks, practical subspecialty updates, and structured opportunities for connection across career stages.

Large study links specific retinal findings to leukemia subtype, predicting remission risk and visual prognosis—prompt eye exams can flag relapse early.

Trial shows AAV8 PDE6A gene therapy doesn’t improve retinitis pigmentosa vision in a year and may cause retinal thinning and VA loss.

The 22nd International Scientific Symposium on Ophthalmic Imaging will take place 18–19 September 2026 in Singapore, marking an expanded scientific scope while maintaining its focus on imaging in research and clinical practice.

Most patients do well on topical therapy, but innovation in IOP-lowering drops remains essential.

The group recommends using “physicians” for doctors and “clinicians” or “health care professionals” for care teams.

The group recommends more precise language such as “physicians” and “clinicians” to reflect medicine’s humanistic and professional responsibilities.

ACP says the label “provider” blurs clinical roles, commercializes care, and erodes trust—urging words that protect medical ethics and relationships.

Lab tests show red‑light myopia devices exceed ANSI safety limits in seconds, fueling urgent calls for independent validation before kids use them.

New AAV therapy for retinitis pigmentosa completes Phase I/II dosing, aiming to protect cones and slow vision loss; first readout targets 2027.

Oluwatosin U. Smith, MD, highlights how the foundation provides education, research, and access-to-care for patients and clinicians globally and locally.

Aaron Y. Lee, MD, MSCI, explains how temporal optical coherence tomography modeling may improve longitudinal disease tracking and clinical decision-making at Angiogenesis 2026.

The primary endpoint of the trial is non-inferiority in the mean change from baseline in best-corrected visual acuity (BCVA) at 52 weeks.

The results of a multicenter controlled clinical trial showed that the device resulted in “a significant improvement in visual acuity (VA) from baseline to month 12.

P. Dee G. Stephenson, MD, FACS, shares insights on evolving LAL technology and best practices for managing the ocular surface before and after surgery.

Lorem ipsum dolor sit amet, consectetur adipiscing elit.

The deal will see MeiraGTx assume development rights to ZipBio’s experimental therapies targeting the complement pathway in geographic atrophy (GA).

Retina specialists showcase innovation and precision in retinal care